Injecting drug users are not the only focus of the AIDS Conference in Vienna next week.

One of the priorities for African delegates will be the release of the results of the CAPRISA 004 microbicide trial next Tuesday, 20 July at 1pm.

This randomised controlled trial in South Africa tested the safety and efficacy of a 1% tenofovir-gel candidate, the first to use an antiretroviral to block infection.

The gel was tested among some 900 volunteers in CAPRISA’s rural Vulindlela site and urban Thekwini site.

Scientists and activists – particularly in the field of HIV prevention – are waiting in suspense to find out if this gel works.

None of the six candidates tested in 11 trials over the past 15 years has been successful yet.

The Global Campaign for Microbicides and Treatment Action Campaign have already organised a satellite session at the conference on the implications of the outcome.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.